Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus chemotherapy for conversion therapy in esophageal squamous cell carcinoma with cervical lymph node metastasis
ChiCTR2300069228Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China
- Start
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pembrolizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by The First Affiliated Hospital of University of Science and Technology of China. Primary endpoint: Surgical conversion rate. Started Dec 2022; status: recruiting.
02
Drugs
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2300069228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069228.